Frontiers15d
Evaluation of Siemens Healthineers’ StrokeSegApp for automated diffusion and perfusion lesion segmentation in patients with ischemic stroke
Patients were consecutively enrolled between 1 September 2008 and 30 June 2013 at Charité, Campus Benjamin Franklin ... Prothena Biosciences, Regeneron Pharmaceuticals, Roche, Syneos, Tau Rx, Vertex ...
Vertex Pharmaceuticals price target raised to $540 from $522 at BofA
BofA analyst Tazeen Ahmad raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $540 from $522 and keeps a Buy rating on the ...
Cautious Outlook on Vertex Pharmaceuticals Amid Journavx Approval and Pricing Concerns
Vertex Pharmaceuticals (VRTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence ...
Yahoo Finance6d
Vertex Pharmaceuticals Stock Jumps as Non-Opioid Painkiller Gets FDA Approval
Vertex Pharmaceuticals' non-opioid painkiller received approval from the Food and Drug Administration. The drugmaker said the twice-daily pill, Journavx, is the first such treatment to hit the ...
Vertex Pharmaceuticals' SWOT analysis: biotech giant's stock faces growth challenges
Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company known for its cystic fibrosis (CF) treatments, is at a critical juncture as it seeks to diversify its portfolio and maintain its ...
Investopedia6d
Vertex Pharmaceuticals Stock Jumps as Non-Opioid Painkiller Gets FDA Approval
JOSEPH PREZIOSO / AFP via Getty Images Vertex Pharmaceuticals' non-opioid painkiller received approval from the Food and Drug Administration. The drugmaker said the twice-daily pill, Journavx ...
Yahoo Finance5d
Vertex Pharmaceuticals price target raised to $433 from $430 at Scotiabank
Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $433 from $430 and keeps a Sector Perform rating on the shares. Vertex’s suzetrigine, branded Journavx ...
Benzinga.com7d
Vertex Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (21 Ratings)
Analysts' ratings for Vertex Pharmaceuticals VRTX over the last quarter vary from bullish to bearish, as provided by 21 analysts. Summarizing their recent assessments, the table below illustrates ...
MarketWatch6d
Vertex Pharmaceuticals stock is soaring. The FDA just approved its potentially game-changing pain treatment.
Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved the company’s non-opioid pain treatment. It’s the first new class ...
Fox Business6d
Vertex Pharmaceuticals' non-opioid pain medication gets FDA approval
A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug Administration (FDA). The company’s "first-in-class" suzetrigine pain pill ...
AOL5d
Is Vertex Pharmaceuticals a Buy Now That the FDA Approved Its New Pain Drug?
Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) are down about 9% from a peak the stock set in November, despite some highly positive news. The U.S. Food and Drug Administration (FDA) approved ...